Albert Bourla, Pfizer CEO (Markus Schreiber/AP Images)
January 30, 2024 07:32 AM ESTUpdated 08:03 AM
Pharma

Pfiz­er's Q4 rev­enue tum­bles 42% amid Covid re­set

Katherine Lewin

News Reporter

Pfiz­er round­ed out a tough year with fourth-quar­ter rev­enue of $14.2 bil­lion, a 42% de­crease com­pared to the same time in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Ex­clu­sive: Jim Wil­son start­up gets FDA green light for first test of gene edit­ing in ba­bies

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ex­clu­sive: Mod­er­na's for­mer top sci­en­tist has a new start­up us­ing AI to im­prove mR­NA ther­a­pies

A service from the Financial Times